We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clarifies When to Report Postapproval CMC Changes
FDA Clarifies When to Report Postapproval CMC Changes
The FDA is clarifying what postapproval chemistry, manufacturing and control changes drugmakers need to report to NDAs, ANDAs and BLAs — with the aim of spurring more flexible regulatory pathways for such changes.